Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $7.5 million.

  • IDEAYA Biosciences' Change in Accured Expenses rose 159.34% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 59.08%. This contributed to the annual value of $10.8 million for FY2024, which is 560.18% up from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Change in Accured Expenses is $7.5 million, which was up 55.03% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Change in Accured Expenses registered a high of $7.5 million during Q3 2025, and its lowest value of -$2.8 million during Q2 2023.
  • In the last 3 years, IDEAYA Biosciences' Change in Accured Expenses had a median value of $2.5 million in 2023 and averaged $2.5 million.
  • Data for IDEAYA Biosciences' Change in Accured Expenses shows a peak YoY increase of 668.11% (in 2023) and a maximum YoY decrease of 399.29% (in 2023) over the last 5 years.
  • Over the past 5 years, IDEAYA Biosciences' Change in Accured Expenses (Quarterly) stood at $476,000 in 2021, then slumped by 32.14% to $323,000 in 2022, then spiked by 668.11% to $2.5 million in 2023, then decreased by 8.34% to $2.3 million in 2024, then soared by 159.34% to $7.5 million in 2025.
  • Its Change in Accured Expenses stands at $7.5 million for Q3 2025, versus $4.8 million for Q2 2025 and $2.9 million for Q1 2025.